#58: MIVT News MIVT Cites Growing Body of Scientific Evidence Validating Company's Strategy to Create Safer, Better Cardiovascular Stents; Company's Proprietary Solutions to Address Widespread Medical Concerns Detailed in Wall Street Journal, JAMA
VANCOUVER, British Columbia--(BUSINESS WIRE)--July 6, 2006--MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems...
#57: MIVT News MIV Therapeutics beschreibt wissenschaftliche und strategische Meilensteine bei der Entwicklung biomedizinischer Technologien der nächsten Generation im Jahr 2005
VANCOUVER, British Columbia--(BUSINESS WIRE)--4. Januar 2006-- Jahresendbericht nennt erfolgreiche und revolutionäre Lösungen im Bereich Arzneimittelabgabe und anderen Gebieten für...
#56: MIVT News MIV Therapeutics Highlights 2005 Scientific and Strategic Milestones in Development of New Generation Biomedical Technologies; Year-End Report Cites Achievements in Breakthrough Drug Delivery and Other Solutions for Multi-Billion-Dollar Markets
VANCOUVER, British Columbia--(BUSINESS WIRE)--Jan. 4, 2006--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery...
#55: MIVT News MIV Therapeutics' Advanced Stent Coating Technologies Praised in Respected Germany-Based Investment Newsletter; Article Targeted to European Financial Community Features MIVT's Innovative Development Program
VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 23, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery...
#54: MIVT News MIV Therapeutics Spotlights Newest Clinical Results of Company's HAp-Based Stent Coating on BiomedDiscoveries.com; Chief Medical Officer Describes Positive Outcomes of Pivotal Study of Biocompatibility Coatings in Interview
LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--BiomedDiscoveries.com -- http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today...
#53: MIVT News MIV Therapeutics Reports Highly Favorable Results in Preclinical Study of Innovative Stroke Prevention Device; Unique Implantable Anti-Stroke Device Progress on Track for Approval and Potential Commercialization
VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 2, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT) (FWB: MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery...
#51: MIVT News MIV Therapeutics Premieres Research into Advanced Polymer-free Drug Delivery Systems at Leading Biomedical Conference; MIVT Premieres Revolutionary Drug Eluting System Based on its Proprietary Hydroxyapatite Coating Technologies
VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 1, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery...
#52: MIVT News MIV Therapeutics stellt neueste Forschungsergebnisse zu seinem fortschrittlichen polymerfreien Arzneimittelabgabesystem auf führender Biomedizinkonferenz vor
VANCOUVER, British Columbia--(BUSINESS WIRE)-1. Dez. 2005-MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), ein führender Entwickler biokompatibler Beschichtungen und moderner...
VANCOUVER, British Columbia--(BUSINESS WIRE)-15. Nov. 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), ein führender Entwickler biokompatibler Beschichtungen und moderner...
#50: MIVT News MIVT's Proprietary Stent Coating Technology Completes Major Long-Term Animal Study with Excellent Results; Six-Month Study Demonstrates Unparalleled Biocompatibility and Safety of MIVT HAp Coatings for Drug-Eluting Stent Applications
VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 15, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery...
#47: MIVT News MIV Therapeutics Invited to Present Latest Data on Breakthrough Biofriendly Coating at Leading Medical Device Conference; Invitation Recognizes Potential of MIVT Proprietary Coating to Improve Stent and Drug-Delivery Effectiveness and Safety
VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 2, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery...
VANCOUVER, British Columbia--(BUSINESS WIRE)-2. Nov. 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), ein führender Entwickler biokompatibler Beschichtungen und moderner...
#45: MIVT News MIV Therapeutics' Proprietary Stent Coating Studies Presented at Major TCT Conference by Independent Researchers; Interim Findings in Long-Term Animal Study Reinforce Superior Biocompatibility and Stent Performance of New Coatings
VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 25, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a developer of next-generation biocompatible stent coatings and drug delivery...
VANCOUVER, British Columbia - (BUSINESS WIRE) - 25. Okt. 2005 - MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), Entwickler von biokompatiblen Stentbeschichtungen und Wirkstoffabgabesystemen der...
#43: MIVT News MIV Therapeutics Officially Named Winner of Prestigious Award for Innovation in Advanced Biomedical Technology; Frost & Sullivan Report Praises MIVT Proprietary Biocompatible Coating Technology for Stents and Other Biomedical Devices
VANCOUVER, British Columbia--(BUSINESS WIRE)--Oct. 21, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a developer of next-generation biocompatible stent coatings and drug delivery...
